Free Trial

Feedback (FDBK) Competitors

Feedback logo
GBX 44.50
+1.00 (+2.30%)
(As of 11/1/2024 ET)

FDBK vs. RENX, COG, INHC, IQAI, DVRG, TRLS, SENS, EMIS, CRW, and INS

Should you be buying Feedback stock or one of its competitors? The main competitors of Feedback include Renalytix (RENX), Cambridge Cognition (COG), Induction Healthcare Group (INHC), IQ-AI (IQAI), DeepVerge (DVRG), Trellus Health (TRLS), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.

Feedback vs.

Feedback (LON:FDBK) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Feedback received 142 more outperform votes than Renalytix when rated by MarketBeat users. However, 74.19% of users gave Renalytix an outperform vote while only 67.07% of users gave Feedback an outperform vote.

CompanyUnderperformOutperform
FeedbackOutperform Votes
165
67.07%
Underperform Votes
81
32.93%
RenalytixOutperform Votes
23
74.19%
Underperform Votes
8
25.81%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Feedback
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Feedback has higher earnings, but lower revenue than Renalytix. Feedback is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£1.02M5.82-£3.49M-£0.26-171.15
Renalytix£2.29M5.80-£33.46M-£0.24-33.33

Feedback's return on equity of -32.67% beat Renalytix's return on equity.

Company Net Margins Return on Equity Return on Assets
FeedbackN/A -32.67% -21.47%
Renalytix N/A -1,073.18%-93.54%

Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.

53.2% of Feedback shares are held by institutional investors. Comparatively, 28.4% of Renalytix shares are held by institutional investors. 10.8% of Feedback shares are held by insiders. Comparatively, 35.7% of Renalytix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Feedback had 1 more articles in the media than Renalytix. MarketBeat recorded 1 mentions for Feedback and 0 mentions for Renalytix. Feedback's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company Overall Sentiment
Feedback Neutral
Renalytix Neutral

Summary

Feedback beats Renalytix on 7 of the 13 factors compared between the two stocks.

Get Feedback News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDBK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDBK vs. The Competition

MetricFeedbackHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£5.93M£218.32M£5.40B£1.58B
Dividend Yield4.56%6.58%5.13%11.08%
P/E Ratio-171.15652.83115.481,723.54
Price / Sales5.82338.721,483.20228,959.04
Price / Cash1.1243.5739.6535.69
Price / Book0.664.924.662.87
Net Income-£3.49M-£5.00M£119.06M£144.80M
7 Day Performance-21.24%0.53%0.80%0.11%
1 Month Performance9.90%-1.12%5.66%-0.16%
1 Year Performance-41.45%10.97%36.76%15.21%

Feedback Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDBK
Feedback
N/AGBX 44.50
+2.3%
N/A-42.1%£5.93M£1.02M-171.1524Gap Up
High Trading Volume
RENX
Renalytix
N/AGBX 8
flat
N/A-81.8%£13.27M£2.29M-33.33102Gap Up
COG
Cambridge Cognition
N/AGBX 28
flat
N/A-57.6%£11.74M£13.08M-700.0080News Coverage
INHC
Induction Healthcare Group
N/AGBX 7.50
flat
N/A-67.3%£7.04M£13.65M-250.0074Gap Down
IQAI
IQ-AI
N/AGBX 1.03
flat
N/A-75.6%£2.27M£538,190.00-13.676Gap Up
DVRG
DeepVerge
N/AN/AN/AN/A£1.14M£12.41M-15.0073
TRLS
Trellus Health
N/AGBX 0.68
flat
N/A-87.1%£1.09M£35,000.00-22.5031Gap Down
SENS
Sensyne Health
N/AN/AN/A+0.0%£583,000.00£7.81M-0.0270Gap Down
EMIS
EMIS Group
N/AGBX 1,920
flat
N/A+0.0%£1.23B£176.86M4,085.111,560
CRW
Craneware
2.3159 of 5 stars
GBX 1,700
-1.2%
GBX 2,700
+58.8%
+23.7%£600.78M£189.27M6,538.46734
INS
Instem
N/AGBX 830
flat
N/A+8.5%£199.62M£61.63M5,928.57500

Related Companies and Tools


This page (LON:FDBK) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners